This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC) (SELECT)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Eisai Inc.
ClinicalTrials.gov Identifier:
NCT01321554
First received: March 10, 2011
Last updated: May 11, 2017
Last verified: April 2017
  Purpose
This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 study to compare the progression free survival of participants with 131 I -refractory DTC and radiographic evidence of disease progression within the prior 12 months, treated with lenvatinib 24 mg by continuous once daily oral dosing versus placebo. The study is conducted in 3 phases: a Prerandomization Phase (screening and baseline period), a Randomization Phase (double-blind treatment period), and an Extension Phase (Optional Open Label (OOL) Lenvatinib Treatment Period and a follow-up period).

Condition Intervention Phase
Thyroid Cancer Drug: Lenvatinib Drug: Placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer

Resource links provided by NLM:


Further study details as provided by Eisai Inc.:

Primary Outcome Measures:
  • Progression Free Survival (PFS) [ Time Frame: Date of randomization to the date of disease progression or death (whichever occurred first), assessed up to data cutoff date (15 Nov 2013) or up to approximately 2.5 years ]
    PFS was defined as the time from the date of randomization to the date of first documentation of disease progression or death (whichever occurred first), as determined by blinded independent imaging review (IIR) using Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 for the double-blind treatment period (Randomization Phase). Disease progression per RECIST v1.1 was defined as at least a 20% relative increase and 5 mm absolute increase in the sum of diameters of target lesions (taking as reference the smallest sum on study), recorded since the treatment started or the appearance of 1 or more new lesions.


Secondary Outcome Measures:
  • Overall Response Rate (ORR) [ Time Frame: Date of randomization to the date of disease progression or death (whichever occurred first), assessed up to data cutoff date (15 Nov 2013) or up to approximately 2.5 years ]
    ORR, defined as the proportion of participants who had best overall response (BOR) of complete response (CR) or partial response (PR) as determined by blinded IIR using RECIST 1.1 for target lesions and assessed by MRI/CT scans (for double blind treatment period i.e. Randomization Phase). CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had to have reduction in short axis to less than 10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. ORR = CR + PR.

  • Overall Survival (OS) [ Time Frame: Date of randomization until date of death from any cause, assessed up to data cutoff date (15 Nov 2013) or up to approximately 2.5 years ]
    Overall survival measured from the date of randomization until date of death from any cause. Overall survival is adjusted with rank preserving structural failure time.

  • Pharmacokinetic (PK) Profile of Lenvatinib: Area Under the Plasma Concentration Curve [ Time Frame: Cycle 1 Day 1 through Cycle 6 Day 1 ]
    AUC was used to determine the total exposure of lenvatinib in blood plasma. From each participant, a total of up to 12 blood samples were collected at the following specified time points: predose, 0.5 to 4 hours postdose, and 6 to 10 hours postdose on Cycle 1/Day 1 and Cycle 1/Day 15; predose and 2 to 12 hours postdose on Cycle 2/Day 1; and predose only on Day 1 of Cycles 3 to 6. The samples were analyzed for the concentration of lenvatinib using validated analytical methods. Population PK model and observed concentration data were used to derive model-predicted lenvatinib PK parameters and lenvatinib exposure (AUC) based on the 24 mg starting dose.


Enrollment: 392
Actual Study Start Date: March 17, 2011
Estimated Study Completion Date: December 1, 2019
Primary Completion Date: November 15, 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Lenvatinib (Randomization Phase)
Participants randomly assigned in a 2:1 ratio to receive blinded study drug (lenvatinib or matching placebo) until documentation of disease progression (confirmed by IIR), development of unacceptable toxicity, or withdrawal of consent.
Drug: Lenvatinib
Lenvatinib 24 mg (two 10-mg and one 4-mg lenvatinib matched capsules) taken orally once daily, continuously. Dose interruptions or reductions were allowed for subjects who experienced treatment-related toxicity.
Other Name: Lenvatinib (Lenvima, E7080)
Placebo Comparator: Placebo (Randomization Phase)
Participants randomly assigned in a 2:1 ratio to receive blinded study drug (lenvatinib or matching placebo) until documentation of disease progression (confirmed by IIR), development of unacceptable toxicity, or withdrawal of consent.
Drug: Placebo
Matching placebo (two 10-mg and one 4-mg lenvatinib matched capsules) taken orally once daily, continuously.
Experimental: Lenvatinib 24 mg (OOL Lenvatinib Treatment Period)
Participants will receive lenvatinib 24 mg, orally once daily until documentation of disease progression (confirmed by investigator's assessment), development of unacceptable toxicity, or withdrawal of consent. Placebo treated participants in the Randomization Phase who have progressive disease confirmed by IIR could request to receive lenvatinib treatment in the OOL Treatment Period.
Drug: Lenvatinib
Lenvatinib 24 mg (two 10-mg and one 4-mg lenvatinib matched capsules) taken orally once daily, continuously. Dose interruptions or reductions were allowed for subjects who experienced treatment-related toxicity.
Other Name: Lenvatinib (Lenvima, E7080)
Experimental: Lenvatinib 20 mg (OOL Lenvatinib Treatment Period)
Participants will receive lenvatinib 20 mg, orally once daily until documentation of disease progression (confirmed by investigator's assessment), development of unacceptable toxicity, or withdrawal of consent. Placebo treated participants in the Randomization Phase who have progressive disease confirmed by IIR could request to receive lenvatinib treatment in the OOL Treatment Period.
Drug: Lenvatinib

Lenvatinib 20 mg (two 10-mg capsules) taken orally once daily, continuously. Dose interruptions or reductions were allowed for subjects who experienced treatment-related toxicity.

The dose of lenvatinib during the OOL Lenvatinib Treatment Period was 24 mg once daily from 03 Oct 2011 until 15 Feb 2013. The dose was lowered at the request of the Data Monitoring Committee to 20 mg on 16 Feb 2013. Thus, more subjects were treated with 24 mg starting dose and the treatment duration was longer for these participants than those whose starting dose was 20 mg.

Other Name: Lenvatinib (Lenvima, E7080)

Detailed Description:
Randomization Phase: Participants will receive blinded study drug (lenvatinib/placebo) in 2:1 ratio until documentation of disease progression (confirmed by independent imaging review), development of unacceptable toxicity, or withdrawal of consent. After having completed the primary analysis, subjects treated with lenvatinib who have not experienced disease progression may request to continue open label lenvatinib at the same dose, according to the clinical judgment of the investigator. Participants who discontinue treatment for any reason other than disease progression will be followed in the Randomization Phase until disease progression or start of another anticancer treatment; these participants then enter the Extension Phase for survival follow-up. Extension Phase: Participants in the placebo arm who have disease progression confirmed by IIR could request to enter the OOL Lenvatinib Treatment Period and receive lenvatinib treatment. Participants will receive lenvatinib treatment until disease progression (investigator's assessment), development of intolerable toxicity, or withdrawal of consent. Participants who had disease progression during the Randomization Phase and did not enter the OOL Lenvatinib Treatment Period and all participants who discontinued lenvatinib treatment in the OOL Lenvatinib Treatment Period will enter the follow-up period. Participants will be followed for survival, and all anticancer treatments will be recorded until the time of death.
  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  1. Histologically or cytologically confirmed diagnosis of one of the following DTC subtypes: Papillary thyroid cancer (PTC) or follicular thyroid cancer (FTC).
  2. Measurable disease according to (RECIST 1.1) and confirmed by central radiographic review.
  3. 131 I-refractory/resistant disease.
  4. Evidence of disease progression within 12 months prior to signing informed consent (+1 month screening window).
  5. Prior treatment with 0 or 1 vascular endothelial growth-factor (VEGF) or vascular endothelial growth-factor receptors (VEGFR) targeted therapy.
  6. Adequate renal, liver, bone marrow, and blood coagulation function, as defined in the protocol.

Exclusion criteria:

  1. Anaplastic or medullary carcinoma of the thyroid
  2. 2 or more prior VEGF/ VEGFR-targeted therapies
  3. Received any anticancer treatment within 21 days or any investigational agent within 30 days prior to the first dose of study drug.

Inclusion criteria for OOL Lenvatinib Treatment Period :

Participants were eligible for lenvatinib treatment in the OOL Lenvatinib Treatment Period if the met the following criteria:

  1. Placebo-treated participants in the Randomization Phase who had progressive disease (PD) confirmed by IIR, and who requested treatment with lenvatinib.
  2. Participants who continued to satisfy specified inclusion and exclusion criteria as presented in the study protocol.
  3. Participants with maximum interval between the day of confirmation of PD by IIR and Cycle 1/Day 1 of the OOL Lenvatinib Treatment Period of less than or equal to 3 months.
  4. No systemic anticancer treatment during the interval between the day of confirmation of PD by the IIR and Cycle 1/Day 1 of the OOL Lenvatinib Treatment Period.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01321554

  Hide Study Locations
Locations
United States, Arkansas
Little Rock, Arkansas, United States
United States, California
La Jolla, California, United States
Los Gatos, California, United States
Mission Viejo, California, United States
Orange, California, United States
Sacramento, California, United States
Torrance, California, United States
United States, Colorado
Aurora, Colorado, United States
United States, District of Columbia
Washington, D.C., District of Columbia, United States
United States, Florida
Orlando, Florida, United States
Weston, Florida, United States
United States, Illinois
Chicago, Illinois, United States
United States, Indiana
Indianapolis, Indiana, United States
United States, Kentucky
Lexington, Kentucky, United States
United States, Maryland
Baltimore, Maryland, United States
United States, Massachusetts
Boston, Massachusetts, United States
United States, Michigan
Detroit, Michigan, United States
Lansing, Michigan, United States
United States, Minnesota
Minneapolis, Minnesota, United States
United States, Missouri
Columbia, Missouri, United States
United States, Nebraska
Omaha, Nebraska, United States
United States, New Hampshire
Lebanon, New Hampshire, United States
United States, New Jersey
Morristown, New Jersey, United States
Neptune City, New Jersey, United States
United States, New York
New York, New York, United States
The Bronx, New York, United States
United States, Ohio
Columbus, Ohio, United States
United States, Oregon
Portland, Oregon, United States
United States, Pennsylvania
Philadelphia, Pennsylvania, United States
United States, Texas
Houston, Texas, United States
United States, Washington
Seattle, Washington, United States
United States, West Virginia
Morgantown, West Virginia, United States
United States, Wisconsin
Milwaukee, Wisconsin, United States
Argentina
Rosario, Provincia de Santa Fe, Argentina
San Salvador de Jujuy, Argentina
Tucuman, Argentina
Australia, New South Wales
St Leonards, New South Wales, Australia
Australia, Queensland
Herston, Queensland, Australia
Australia, Tasmania
Hobart, Tasmania, Australia
Australia, Victoria
Melbourne, Victoria, Australia
Australia
Heidelberg, Australia
Austria
Wien, Austria
Belgium
Bruxelles, Belgium
Edegem, Belgium
Namur, Belgium
Brazil
Brasilia - DF, Brazil
Joinville, Brazil
Movo Hamburgo, Brazil
Rio de Janeiro, Brazil
Salvador/BA, Brazil
Sao Paulo - SP, Brazil
Sao Paulo, Sao Paulo, Brazil
Canada, Ontario
London, Ontario, Canada
Toronto, Ontario, Canada
Canada, Quebec
Montreal, Quebec, Canada
Canada
Quebec, Canada
Chile
Santiago, Chile
Temuco, Chile
Vina del Mar, Chile
Czechia
Olomouc, Czechia
Denmark
Odense, Denmark
France
Angers, France
Bordeaux, France
Caen, France
Clermont-Ferrand, France
Dijon, France
Lille, France
Lyon, France
Marseille, France
Nice, France
Paris, France
Strasbourg, France
Vandoeuvre Les Nancy, France
Villejuif, France
Germany
Essen, Germany
Hannover, Germany
Leipzig, Germany
Minz, Germany
Munchen, Germany
Tubingen, Germany
Wurzburg, Germany
Italy
Catania, Italy
Livorno, Italy
Milano, Italy
Monserrato, Italy
Napoli, Italy
Padova, Italy
Pisa, Italy
Roma, Italy
Rozzano, Italy
Torino, Italy
Viagrande, Italy
Japan
Nagoya, Aichi, Japan
Kashiwa, Chiba, Japan
Fukui-city, Fukui, Japan
Kobe-city, Hyogo, Japan
Koto-ku, Tokyo, Japan
Korea, Republic of
Daejeon, Korea, Republic of
Gyeonggi-do, Korea, Republic of
Seoul, Korea, Republic of
Uijeongbu, Korea, Republic of
Poland
Gliwice, Poland
Kielce, Poland
Poznan, Poland
Portugal
Lisboa, Portugal
Porto, Portugal
Romania
Bucharest, Romania
Cluj-Napoca, Romania
Russian Federation
Krasnodar, Russian Federation
Kursk, Russian Federation
Obninsk, Russian Federation
Ufa, Russian Federation
Spain
Malaga, Andalucia, Spain
Barcelona, Cataluna, Spain
La Coruna, Galicia, Spain
Barcelona, Spain
L'Hospitalet de Llobregat, Spain
Madrid, Spain
Sweden
Goteborg, Sweden
Lund, Sweden
Stockholm, Sweden
Thailand
Bangkok, Thailand
Chiangmai, Thailand
Khon Kaen, Thailand
Pathumwan, Thailand
United Kingdom
Aberdeen, United Kingdom
Glasgow, United Kingdom
London, United Kingdom
Manchester, United Kingdom
Sheffield, United Kingdom
Sutton, United Kingdom
Sponsors and Collaborators
Eisai Inc.
Investigators
Study Director: Eisa Inc Eisai Inc.
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Eisai Inc.
ClinicalTrials.gov Identifier: NCT01321554     History of Changes
Other Study ID Numbers: E7080-G000-303
Study First Received: March 10, 2011
Results First Received: March 13, 2015
Last Updated: May 11, 2017

Additional relevant MeSH terms:
Thyroid Diseases
Thyroid Neoplasms
Endocrine System Diseases
Endocrine Gland Neoplasms
Neoplasms by Site
Neoplasms
Head and Neck Neoplasms
Lenvatinib
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on August 22, 2017